Početna › Neoplazije po histološkom tipu › Texas
Kliničke studije za Neoplazije po histološkom tipu u državi Texas
6 studija za Neoplazije po histološkom tipu traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
Službeni tekst studije (engleski)
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- UT Southwestern Medical Center, Dallas
- The University of Texas M.D. Anderson Cancer Center, Houston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT05874921HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
36 Months – 22 Years · Oba spola · Ažurirano 4. ruj 2026. · NCT03911388Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06001788Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. srp 2026. · NCT04198766Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Texas Oncology - Austin Central, Austin
- World Research Link, Baytown
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT06463665A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 27. svi 2026. · NCT03093116Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.